Immune checkpoint blockade in infectious diseases

被引：399
作者：
Wykes, Michelle N. [1 ]
Lewin, Sharon R. [2 ,3 ,4 ,5 ]
机构：
[1] QIMR Berghofer Med Res Inst, 300 Herston Rd, Brisbane, Qld 4006, Australia
[2] Univ Melbourne, Peter Doherty Inst Infect & Immun, Melbourne, Vic 3000, Australia
[3] Royal Melbourne Hosp, Melbourne, Vic 3000, Australia
[4] Alfred Hosp, Dept Infect Dis, Melbourne, Vic 3004, Australia
[5] Monash Univ, Melbourne, Vic 3004, Australia
来源：
NATURE REVIEWS IMMUNOLOGY | 2018年 / 18卷 / 02期
基金：
英国医学研究理事会;
关键词：
T-CELL EXHAUSTION; PROGRAMMED DEATH-1; PD-1; EXPRESSION; UP-REGULATION; LYMPHOCYTE ATTENUATOR; ACQUIRED-IMMUNITY; B-LYMPHOCYTE; PLASMODIUM-FALCIPARUM; INHIBITORY RECEPTORS; ANTI-PD-L1; ANTIBODY;
D O I：
10.1038/nri.2017.112
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
The upregulation of immune checkpoint molecules, such as programmed cell death protein 1 (PD1) and cytotoxic T lymphocyte antigen 4 (CTLA4), on immune cells occurs during acute infections, such as malaria, as well as during chronic persistent viral infections, including HIV and hepatitis B virus. These pathways are important for preventing immune-driven pathology but can also limit immune-mediated clearance of the infection. The recent success of immune checkpoint blockade in cancer therapy suggests that targeting these pathways would also be effective for preventing and treating a range of infectious diseases. Here, we review our current understanding of immune checkpoint pathways in the pathogenesis of infectious diseases and discuss the potential for therapeutically targeting these pathways in this setting.
引用
收藏
页码：91 / 104
页数：14
相关论文
共 50 条
  • [41] Immune checkpoint receptors in cancer: redundant by design?
    Li, Jing
    Ni, Ling
    Dong, Chen
    CURRENT OPINION IN IMMUNOLOGY, 2017, 45 : 37 - 42
  • [42] Coinhibitory Receptor expression and immune Checkpoint Blockade: Maintaining a Balance in CD8+ T Cell Responses to Chronic viral infections and Cancer
    Okoye, Isobel S.
    Houghton, Michael
    Tyrrell, Lorne
    Barakat, Khaled
    Elahi, Shokrollah
    FRONTIERS IN IMMUNOLOGY, 2017, 8
  • [43] Fluorescence imaging of tumor immune contexture in immune checkpoint blockade therapy
    Pan, Xiao
    Gao, Antian
    Lin, Zitong
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2022, 106
  • [44] Local and Targeted Delivery of Immune Checkpoint Blockade Therapeutics
    Han, Xiao
    Li, Hongjun
    Zhou, Daojia
    Chen, Zhaowei
    Gu, Zhen
    ACCOUNTS OF CHEMICAL RESEARCH, 2020, 53 (11) : 2521 - 2533
  • [45] Progress and Challenges of Predictive Biomarkers for Immune Checkpoint Blockade
    Lei, Yanna
    Li, Xiaoying
    Huang, Qian
    Zheng, Xiufeng
    Liu, Ming
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [46] Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma
    Maxwell, Russell
    Jackson, Christopher M.
    Lim, Michael
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2017, 18 (08)
  • [47] Immune Checkpoint Blockade and Hematopoietic Stem Cell Transplant
    Merryman, Reid W.
    Armand, Philippe
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2017, 12 (01) : 44 - 50
  • [48] Prospects for combining immune checkpoint blockade with PARP inhibition
    Li, Anping
    Yi, Ming
    Qin, Shuang
    Chu, Qian
    Luo, Suxia
    Wu, Kongming
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2019, 12 (01)
  • [49] Metabolic predictors of response to immune checkpoint blockade therapy
    Shorer, Ofir
    Yizhak, Keren
    ISCIENCE, 2023, 26 (11)
  • [50] Perspective: cancer vaccines in the era of immune checkpoint blockade
    Cebon, Jonathan
    MAMMALIAN GENOME, 2018, 29 (11-12) : 703 - 713
12345